Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Pipeline Review, H1 2018
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Pipeline Review, H1 2018
SUMMARY
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Cell division protein kinase 6 (CDK6) is an enzyme encoded by the CDK6 gene. It is involved in initiation and maintenance of cell cycle exit during cell differentiation, prevents cell proliferation and regulates negatively cell differentiation. It is required during thymocyte development. It promotes the production of newborn neurons, probably by modulating G1 length, changes in the actin cytoskeleton including loss of stress fibers, and enhanced motility during cell differentiation. It prevents myeloid differentiation by interfering with RUNX1 and reducing its transcription transactivation-activity.
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 2, 2, 1, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas which include indications Breast Cancer, Metastatic Breast Cancer, Mantle Cell Lymphoma, Colorectal Cancer, Lymphoma, Non-Small Cell Lung Cancer, Liposarcoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Oligodendroglioma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Recurrent Glioblastoma Multiforme (GBM), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), AIDS - Related Cancer, Anaplastic Oligoastrocytoma, Astrocytoma, B-Cell Leukemia, Brain Tumor, Chemotherapy Induced Myelosuppression, Chordoma, Colon Cancer, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Duodenal Cancer, Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Epstein-Barr Virus (HHV-4) Infections, Fallopian Tube Cancer, Gastric Cancer, Germ Cell Tumors, Glioblastoma Multiforme (GBM), Glioma, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Leukemias, Melanoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Ovarian Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Neuroendocrine Tumors, Peritoneal Cancer, Primary CNS Lymphoma, Prostate Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis, Small-Cell Lung Cancer, Solid Tumor, Squamous Non-Small Cell Lung Cancer, Thymic Carcinoma and Unspecified B-Cell Lymphomas.
The latest report Cyclin Dependent Kinase 6 - Pipeline Review, H1 2018, outlays comprehensive information on the Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Cell division protein kinase 6 (CDK6) is an enzyme encoded by the CDK6 gene. It is involved in initiation and maintenance of cell cycle exit during cell differentiation, prevents cell proliferation and regulates negatively cell differentiation. It is required during thymocyte development. It promotes the production of newborn neurons, probably by modulating G1 length, changes in the actin cytoskeleton including loss of stress fibers, and enhanced motility during cell differentiation. It prevents myeloid differentiation by interfering with RUNX1 and reducing its transcription transactivation-activity.
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 2, 2, 1, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas which include indications Breast Cancer, Metastatic Breast Cancer, Mantle Cell Lymphoma, Colorectal Cancer, Lymphoma, Non-Small Cell Lung Cancer, Liposarcoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Oligodendroglioma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Recurrent Glioblastoma Multiforme (GBM), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), AIDS - Related Cancer, Anaplastic Oligoastrocytoma, Astrocytoma, B-Cell Leukemia, Brain Tumor, Chemotherapy Induced Myelosuppression, Chordoma, Colon Cancer, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Duodenal Cancer, Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Epstein-Barr Virus (HHV-4) Infections, Fallopian Tube Cancer, Gastric Cancer, Germ Cell Tumors, Glioblastoma Multiforme (GBM), Glioma, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Leukemias, Melanoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Ovarian Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Neuroendocrine Tumors, Peritoneal Cancer, Primary CNS Lymphoma, Prostate Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis, Small-Cell Lung Cancer, Solid Tumor, Squamous Non-Small Cell Lung Cancer, Thymic Carcinoma and Unspecified B-Cell Lymphomas.
The latest report Cyclin Dependent Kinase 6 - Pipeline Review, H1 2018, outlays comprehensive information on the Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22)
- The report reviews Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Overview
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Beta Pharma Inc
Eli Lilly and Co
G1 Therapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
MEI Pharma Inc
Novartis AG
Onconova Therapeutics Inc
Pfizer Inc
Sihuan Pharmaceutical Holdings Group Ltd
Teijin Pharma Ltd
ViroStatics srl
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Drug Profiles
abemaciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPI-1178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-1T38 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GZ-381 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HEC-80797 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ON-123300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palbociclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ribociclib succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-6390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK1, CDK4 and CDK6 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK4 and CDK6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-3177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trilaciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
voruciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-2370 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XZP-3287 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Product Development Milestones
Featured News & Press Releases
Feb 15, 2018: Quebec and New Brunswick Become First Provinces to Provide Public Funding of IBRANCE for the First-Line Treatment of Metastatic Breast Cancer
Jan 08, 2018: MEI Pharma Announces FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib
Jan 03, 2018: Novartis Kisqali received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Dec 21, 2017: MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports
Dec 13, 2017: First-line Ribociclib Improves PFS in Pre- and Peri-menopausal Women with HR-positive, HER2-negative Advanced Breast Cancer
Dec 12, 2017: SMC has recommended Ibrance(palbociclib) for use within NHS Scotland for previously untreated HR+/HER2- metastatic breast cancer
Dec 11, 2017: Ibrance is accepted for restricted use within NHS Scotland
Dec 06, 2017: Updated Data From Phase 3 Trial Of IBRANCE (Palbociclib) Plus Letrozole In Er+, Her2- Metastatic Breast Cancer Confirm Improvement In Progression-Free Survival
Dec 06, 2017: Kisqali first and only CDK4/6 inhibitor to show superior efficacy vs. oral endocrine therapy as 1L treatment in randomized Phase III trial in premenopausal women with HR+/HER2- advanced breast cancer
Nov 23, 2017: Researchers at Washington University report: DiviTum can evaluate the biologic activity of blockbuster breast cancer drug after two weeks
Nov 16, 2017: Novartis Advanced Breast Cancer Drug Kisqali (ribociclib) is First Cancer Treatment Recommended by NICE Under Updated Cancer Appraisal Process
Nov 14, 2017: Novartis To Present Data on Breast Cancer Drug Ribociclib At Upcoming 40th Annual San Antonio Breast Cancer Symposium (SABCS)
Nov 08, 2017: Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
Nov 06, 2017: G1 Therapeutics Announces Publication in Cancer Discovery Demonstrating That CDK4/6 Inhibition Enhances the Anti-Tumor T Cell Response
Nov 03, 2017: Pancreatic cancer patients to benefit from breast cancer drug
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Overview
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Beta Pharma Inc
Eli Lilly and Co
G1 Therapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
MEI Pharma Inc
Novartis AG
Onconova Therapeutics Inc
Pfizer Inc
Sihuan Pharmaceutical Holdings Group Ltd
Teijin Pharma Ltd
ViroStatics srl
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Drug Profiles
abemaciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPI-1178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-1T38 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GZ-381 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HEC-80797 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ON-123300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palbociclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ribociclib succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-6390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK1, CDK4 and CDK6 for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK4 and CDK6 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRX-3177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trilaciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
voruciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-2370 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XZP-3287 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Product Development Milestones
Featured News & Press Releases
Feb 15, 2018: Quebec and New Brunswick Become First Provinces to Provide Public Funding of IBRANCE for the First-Line Treatment of Metastatic Breast Cancer
Jan 08, 2018: MEI Pharma Announces FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib
Jan 03, 2018: Novartis Kisqali received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Dec 21, 2017: MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports
Dec 13, 2017: First-line Ribociclib Improves PFS in Pre- and Peri-menopausal Women with HR-positive, HER2-negative Advanced Breast Cancer
Dec 12, 2017: SMC has recommended Ibrance(palbociclib) for use within NHS Scotland for previously untreated HR+/HER2- metastatic breast cancer
Dec 11, 2017: Ibrance is accepted for restricted use within NHS Scotland
Dec 06, 2017: Updated Data From Phase 3 Trial Of IBRANCE (Palbociclib) Plus Letrozole In Er+, Her2- Metastatic Breast Cancer Confirm Improvement In Progression-Free Survival
Dec 06, 2017: Kisqali first and only CDK4/6 inhibitor to show superior efficacy vs. oral endocrine therapy as 1L treatment in randomized Phase III trial in premenopausal women with HR+/HER2- advanced breast cancer
Nov 23, 2017: Researchers at Washington University report: DiviTum can evaluate the biologic activity of blockbuster breast cancer drug after two weeks
Nov 16, 2017: Novartis Advanced Breast Cancer Drug Kisqali (ribociclib) is First Cancer Treatment Recommended by NICE Under Updated Cancer Appraisal Process
Nov 14, 2017: Novartis To Present Data on Breast Cancer Drug Ribociclib At Upcoming 40th Annual San Antonio Breast Cancer Symposium (SABCS)
Nov 08, 2017: Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
Nov 06, 2017: G1 Therapeutics Announces Publication in Cancer Discovery Demonstrating That CDK4/6 Inhibition Enhances the Anti-Tumor T Cell Response
Nov 03, 2017: Pancreatic cancer patients to benefit from breast cancer drug
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.3), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Products under Development by Companies, H1 2018 (Contd.4), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Beta Pharma Inc, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by G1 Therapeutics Inc, H1 2018
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Pipeline by MEI Pharma Inc, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by Onconova Therapeutics Inc, H1 2018
Pipeline by Pfizer Inc, H1 2018
Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, H1 2018
Pipeline by Teijin Pharma Ltd, H1 2018
Pipeline by ViroStatics srl, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.2), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.3), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Products under Development by Companies, H1 2018 (Contd.4), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Beta Pharma Inc, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by G1 Therapeutics Inc, H1 2018
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Pipeline by MEI Pharma Inc, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by Onconova Therapeutics Inc, H1 2018
Pipeline by Pfizer Inc, H1 2018
Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, H1 2018
Pipeline by Teijin Pharma Ltd, H1 2018
Pipeline by ViroStatics srl, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
COMPANIES MENTIONED
Beta Pharma Inc
Eli Lilly and Co
G1 Therapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
MEI Pharma Inc
Novartis AG
Onconova Therapeutics Inc
Pfizer Inc
Sihuan Pharmaceutical Holdings Group Ltd
Teijin Pharma Ltd
ViroStatics srl
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
COMPANIES MENTIONED
Beta Pharma Inc
Eli Lilly and Co
G1 Therapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
MEI Pharma Inc
Novartis AG
Onconova Therapeutics Inc
Pfizer Inc
Sihuan Pharmaceutical Holdings Group Ltd
Teijin Pharma Ltd
ViroStatics srl
